Ying Gan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ying Gan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Qian Zhang
Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
2 shared publications Xiaofei Wang
Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center National Research Center for Genitourinary Oncology Beijing China
2 shared publicationsAolin Li
Department of Urology Peking University First Hospital Beijing China
1 shared publication- Chaojie Wang
Henan University
1 shared publication - Chenchen Huang
Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center National Research Center for Genitourinary Oncology Beijing China
1 shared publication Congcong Cao
Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University Shenzhen China
1 shared publication
Latest Publications
- Open Access
- 27 July 2025
- Published by Wiley in Aging Cell
- Vol. 24 (10) , e70180
Single‐Cell Sequencing Reveals That CD4+ T Cells Eliminate Senescent Prostate Epithelium to Delay Progression of Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is an age‐related condition characterized by progressive prostate enlargement driven in part by the accumulation of senescent epithelial cells and their pro‐inflammatory secretome. Using human single‐cell RNA sequencing and laser capture microdissection, we identified C‐X‐C Motif Chemokine Ligand 13 (CXCL13) as a key chemokine secreted by senescent prostate epithelial cells. CXCL13 recruits CD4+ T cells via the C‐X‐C Chemokine Receptor Type 5 (CXCR5) receptor, facilitating immune recognition through human leukocyte antigen–DR isotype (HLA‐DR) and promoting senescent cell clearance. Functional assays revealed that CD4+ cytotoxic T lymphocytes (CTLs) mediate this clearance, while regulatory T cells (Tregs) suppress it, forming a functional dichotomy. Immunohistochemistry, transwell migration, and co‐culture assays confirmed this CXCL13–CXCR5–HLA‐DR axis. In a testosterone‐induced BPH mouse model, CXCL13 treatment enhanced CD4+ T cell infiltration and reduced epithelial senescence, while CD4+ T cell depletion reversed these effects. Single‐cell transcriptomics in mice further validated increased CXCL13 expression and CD4+ T cell engagement. These findings uncover a critical immune surveillance mechanism in BPH and suggest that targeting the CXCL13–CD4+ T cell axis may offer a novel therapeutic strategy for age‐related prostate enlargement.
- 27 July 2025
- Published by Wiley in Aging Cell
- Vol. 24 (10) , e70180
Open AccessSingle‐Cell Sequencing Reveals That CD4+ T Cells Eliminate Senescent Prostate Epithelium to Delay Progression of Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is an age‐related condition characterized by progressive prostate enlargement driven in part by the accumulation of senescent epithelial cells and their pro‐inflammatory secretome. Using human single‐cell RNA sequencing and laser capture microdissection, we identified C‐X‐C Motif Chemokine Ligand 13 (CXCL13) as a key chemokine secreted by senescent prostate epithelial cells. CXCL13 recruits CD4+ T cells via the C‐X‐C Chemokine Receptor Type 5 (CXCR5) receptor, facilitating immune recognition through human leukocyte antigen–DR isotype (HLA‐DR) and promoting senescent cell clearance. Functional assays revealed that CD4+ cytotoxic T lymphocytes (CTLs) mediate this clearance, while regulatory T cells (Tregs) suppress it, forming a functional dichotomy. Immunohistochemistry, transwell migration, and co‐culture assays confirmed this CXCL13–CXCR5–HLA‐DR axis. In a testosterone‐induced BPH mouse model, CXCL13 treatment enhanced CD4+ T cell infiltration and reduced epithelial senescence, while CD4+ T cell depletion reversed these effects. Single‐cell transcriptomics in mice further validated increased CXCL13 expression and CD4+ T cell engagement. These findings uncover a critical immune surveillance mechanism in BPH and suggest that targeting the CXCL13–CD4+ T cell axis may offer a novel therapeutic strategy for age‐related prostate enlargement.
- Open Access
- 9 June 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (6) , e906
ZNF677 suppresses renal cell carcinoma progression through N6‐methyladenosine and transcriptional repression of CDKN3
Background: Studies on biological functions of N6‐methyladenosine (m6A) modification in mRNA have sprung up in recent years. Previous studies have reported m6A can determine mRNA fate and play a pivotal role in tumour development and progression. The zinc finger protein 677 (ZNF677) belongs to the zinc finger protein family and possesses transcription factor activity by binding sequence‐specific DNA.Methods: The expression of ZNF677 and its clinicopathological impact were evaluated in renal cell carcinoma (RCC) patients. The m6A level of ZNF677 was determined by m6A methylated RNA immunoprecipitation‐sequencing (MeRIP‐seq) and MeRIP‐qPCR in RCC tissues and adjacent normal tissues. RNA immunoprecipitation‐qPCR (RIP‐qPCR) and luciferase assays were performed to identify the targeted effect of IGF2BP2 and YTHDF1 on ZNF677. RCC cells and subcutaneous models uncovered the role of ZNF677 methylated by CRISPR/dCas13b‐METTL3 in tumour growth. ZNF677‐binding sites in the CDKN3 promoter were investigated by chromatin immunoprecipitation (ChIP) and luciferase assays.Results: ZNF677 is frequently downregulated in RCC tissues and its low expression is associated with unfavourable prognosis and decreased m6A modification level. Further, we find the m6A‐modified coding sequence (CDS) of ZNF677 positively regulates its translation and mRNA stability via binding with YTHDF1 and IGF2BP2, respectively. Targeted specific methylation of ZNF677 m6A by CRISPR/dCas13b‐METLL3 system can significantly increase the m6A and expression level of ZNF677, and dramatically inhibit cell proliferation and induce cell apoptosis of RCC cells. In addition, ZNF677 exerted its tumour suppressor functions in RCC cells through transcriptional repression of CDKN3 via binding to its promoter. In vitro and clinical data confirm the negative roles of ZNF677/CDKN3 in tumour growth and progression of RCC.Conclusion: ZNF677 functions as a tumour suppressor and is frequently silenced via m6A modification in RCC, which may highlight m6A methylation‐based approach for RCC diagnosis and therapy.
- 9 June 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (6) , e906
Open AccessZNF677 suppresses renal cell carcinoma progression through N6‐methyladenosine and transcriptional repression of CDKN3
Background: Studies on biological functions of N6‐methyladenosine (m6A) modification in mRNA have sprung up in recent years. Previous studies have reported m6A can determine mRNA fate and play a pivotal role in tumour development and progression. The zinc finger protein 677 (ZNF677) belongs to the zinc finger protein family and possesses transcription factor activity by binding sequence‐specific DNA.Methods: The expression of ZNF677 and its clinicopathological impact were evaluated in renal cell carcinoma (RCC) patients. The m6A level of ZNF677 was determined by m6A methylated RNA immunoprecipitation‐sequencing (MeRIP‐seq) and MeRIP‐qPCR in RCC tissues and adjacent normal tissues. RNA immunoprecipitation‐qPCR (RIP‐qPCR) and luciferase assays were performed to identify the targeted effect of IGF2BP2 and YTHDF1 on ZNF677. RCC cells and subcutaneous models uncovered the role of ZNF677 methylated by CRISPR/dCas13b‐METTL3 in tumour growth. ZNF677‐binding sites in the CDKN3 promoter were investigated by chromatin immunoprecipitation (ChIP) and luciferase assays.Results: ZNF677 is frequently downregulated in RCC tissues and its low expression is associated with unfavourable prognosis and decreased m6A modification level. Further, we find the m6A‐modified coding sequence (CDS) of ZNF677 positively regulates its translation and mRNA stability via binding with YTHDF1 and IGF2BP2, respectively. Targeted specific methylation of ZNF677 m6A by CRISPR/dCas13b‐METLL3 system can significantly increase the m6A and expression level of ZNF677, and dramatically inhibit cell proliferation and induce cell apoptosis of RCC cells. In addition, ZNF677 exerted its tumour suppressor functions in RCC cells through transcriptional repression of CDKN3 via binding to its promoter. In vitro and clinical data confirm the negative roles of ZNF677/CDKN3 in tumour growth and progression of RCC.Conclusion: ZNF677 functions as a tumour suppressor and is frequently silenced via m6A modification in RCC, which may highlight m6A methylation‐based approach for RCC diagnosis and therapy.
- 1 November 2009
- Published by Taylor & Francis in Journal of Asian Natural Products Research
- Vol. 11 (11) , 978-984
Synthesis and evaluation of solanesol derivatives as novel potent synergistic agents
Novel solanesylpiperazinotriamines as well as their N-aryl-substituted analogs were synthesized starting from solanesol through a multistep procedure. Their structures were confirmed by IR, 1H NMR, MS, and elemental analysis. The preliminary results indicated that these novel derivatives were preferentially toxic against tumor cells, and at non-cytotoxic concentration, the synergistic effect of solanesyltriamines (3a and 3c) was even superior to that of N,N′-bis(3,4-dimethoxybenzyl)-N-solanesylethylenediamine. Interestingly, the cytotoxicity of solanesylpiperazinotriamine derivatives was markedly enhanced when conjugating with aryl pharmacophores (7–9).
- 1 November 2009
- Published by Taylor & Francis in Journal of Asian Natural Products Research
- Vol. 11 (11) , 978-984
Synthesis and evaluation of solanesol derivatives as novel potent synergistic agents
Novel solanesylpiperazinotriamines as well as their N-aryl-substituted analogs were synthesized starting from solanesol through a multistep procedure. Their structures were confirmed by IR, 1H NMR, MS, and elemental analysis. The preliminary results indicated that these novel derivatives were preferentially toxic against tumor cells, and at non-cytotoxic concentration, the synergistic effect of solanesyltriamines (3a and 3c) was even superior to that of N,N′-bis(3,4-dimethoxybenzyl)-N-solanesylethylenediamine. Interestingly, the cytotoxicity of solanesylpiperazinotriamine derivatives was markedly enhanced when conjugating with aryl pharmacophores (7–9).